Market Research Logo

Seizures - Pipeline Review, H2 2016

Seizures - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Seizures - Pipeline Review, H2 2016’, provides an overview of the Seizures pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seizures and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Seizures
  • The report reviews pipeline therapeutics for Seizures by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Seizures therapeutics and enlists all their major and minor projects
  • The report assesses Seizures therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Seizures
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Seizures
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Seizures Overview
Therapeutics Development
Pipeline Products for Seizures - Overview
Pipeline Products for Seizures - Comparative Analysis
Seizures - Therapeutics under Development by Companies
Seizures - Therapeutics under Investigation by Universities/Institutes
Seizures - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Seizures - Products under Development by Companies
Seizures - Products under Investigation by Universities/Institutes
Seizures - Companies Involved in Therapeutics Development
Adamas Pharmaceuticals, Inc.
Advicenne
Alexza Pharmaceuticals, Inc.
Biscayne Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc.
Eisai Co., Ltd.
GW Pharmaceuticals Plc
INSYS Therapeutics, Inc.
Lotus Pharmaceutical Co., Ltd.
Marinus Pharmaceuticals, Inc.
Neurelis, Inc.
Novartis AG
OPKO Health, Inc.
Pfizer Inc.
PTC Therapeutics, Inc.
Sage Therapeutics, Inc.
SciFluor Life Sciences, LLC
Shire Plc
SK Biopharmaceuticals Co., Ltd.
Suda Ltd
Turing Pharmaceuticals AG
UCB S.A.
Ultragenyx Pharmaceutical Inc.
Upsher-Smith Laboratories, Inc.
Xenon Pharmaceuticals Inc.
XERIS Pharmaceuticals, Inc.
Zogenix, Inc.
Zynerba Pharmaceuticals, Inc.
Seizures - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADS-4101 - Drug Profile
ADV-6208 - Drug Profile
ADV-6770 - Drug Profile
alprazolam - Drug Profile
AMPX-0079 - Drug Profile
ataluren - Drug Profile
BIS-001 - Drug Profile
brivaracetam - Drug Profile
cannabidiol - Drug Profile
cannabidiol - Drug Profile
CCG-63802 - Drug Profile
CHEC-9 - Drug Profile
clobazam - Drug Profile
CNSA-004 - Drug Profile
CPP-115 - Drug Profile
CUR-1916 - Drug Profile
diazepam - Drug Profile
diazepam - Drug Profile
everolimus - Drug Profile
fenfluramine hydrochloride - Drug Profile
fosphenytoin sodium - Drug Profile
ganaxolone - Drug Profile
lacosamide - Drug Profile
levetiracetam - Drug Profile
levetiracetam ER - Drug Profile
lorazepam - Drug Profile
LSPGR-1 - Drug Profile
magnesium valproate hydrate - Drug Profile
MB-003 - Drug Profile
midazolam hydrochloride - Drug Profile
midazolam hydrochloride - Drug Profile
midazolam hydrochloride - Drug Profile
midazolam hydrochloride - Drug Profile
Oligonucleotide for Dravet Syndrome - Drug Profile
perampanel - Drug Profile
pregabalin - Drug Profile
SAGE-217 - Drug Profile
SAGE-689 - Drug Profile
selurampanel - Drug Profile
sepranolone - Drug Profile
SF-0034 - Drug Profile
Small Molecule for Stroke and Epilepsy - Drug Profile
Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
Small Molecules for Seizure Disorders - Drug Profile
Small Molecules for Seizures - Drug Profile
TG-4155 - Drug Profile
TRP-001 - Drug Profile
TUR-004 - Drug Profile
TUR-005 - Drug Profile
UX-007 - Drug Profile
YKP-3089 - Drug Profile
ZYN-002 - Drug Profile
Seizures - Dormant Projects
Seizures - Discontinued Products
Seizures - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Seizures, H2 2016
Number of Products under Development for Seizures - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016
Seizures - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
Seizures - Pipeline by Advicenne, H2 2016
Seizures - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016
Seizures - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016
Seizures - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
Seizures - Pipeline by Eisai Co., Ltd., H2 2016
Seizures - Pipeline by GW Pharmaceuticals Plc, H2 2016
Seizures - Pipeline by INSYS Therapeutics, Inc., H2 2016
Seizures - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016
Seizures - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
Seizures - Pipeline by Neurelis, Inc., H2 2016
Seizures - Pipeline by Novartis AG, H2 2016
Seizures - Pipeline by OPKO Health, Inc., H2 2016
Seizures - Pipeline by Pfizer Inc., H2 2016
Seizures - Pipeline by PTC Therapeutics, Inc., H2 2016
Seizures - Pipeline by Sage Therapeutics, Inc., H2 2016
Seizures - Pipeline by SciFluor Life Sciences, LLC, H2 2016
Seizures - Pipeline by Shire Plc, H2 2016
Seizures - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Seizures - Pipeline by Suda Ltd, H2 2016
Seizures - Pipeline by Turing Pharmaceuticals AG , H2 2016
Seizures - Pipeline by UCB S.A., H2 2016
Seizures - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2016
Seizures - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016
Seizures - Pipeline by Xenon Pharmaceuticals Inc., H2 2016
Seizures - Pipeline by XERIS Pharmaceuticals, Inc., H2 2016
Seizures - Pipeline by Zogenix, Inc., H2 2016
Seizures - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Seizures - Dormant Projects, H2 2016
Seizures - Dormant Projects (Contd..1), H2 2016
Seizures - Dormant Projects (Contd..2), H2 2016
Seizures - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Seizures, H2 2016
Number of Products under Development for Seizures - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report